Published in J Clin Invest on February 01, 1974
Gonococci causing disseminated gonococcal infection are resistant to the bactericidal action of normal human sera. J Clin Invest (1976) 5.54
Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity. J Clin Invest (1976) 2.45
Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies. J Clin Invest (1976) 1.78
Complete absence of the third component of complement in man. J Clin Invest (1975) 1.75
Protective role of complement in experimental Escherichia coli endocarditis. Infect Immun (1977) 1.57
Deficiency of the sixth component of complement and susceptibility to Neisseria meningitidis infections: studies in 10 families and five isolated cases. Immunology (1987) 1.29
Hereditary deficiency of the seventh component of complement. J Clin Invest (1975) 1.26
Hereditary deficiency of the sixth component of complement in man. II. Studies of hemostasis. J Clin Invest (1974) 1.20
A case of deficiency of the seventh component of complement in man. Biological properties of a C7-deficient serum and description of a C7-inactivating principle. Clin Exp Immunol (1975) 1.06
Genetic control of the eighth component of complement. J Clin Invest (1979) 1.03
Simultaneous occurrence of hereditary C6 and C2 deficiency in a French-Canadian family. Immunology (1979) 1.01
Combined hereditary deficiency of the sixth component of complement and factor VIII coagulant activity in a Dutch family. Clin Exp Immunol (1982) 0.99
Recurrent bacterial meningitis in patients with genetic defects of terminal complement components. Clin Exp Immunol (1980) 0.95
Hereditary deficiency of the fifth component of complement in man. II. Biological properties of C5-deficient human serum. J Clin Invest (1976) 0.92
Neisseria meningitidis bacteremia in association with deficiency of the sixth component of complement. Infect Immun (1979) 0.88
Inherited deficiency of the seventh component of complement associated with nephritis. Propensity to formation of C56 and related C7-consuming activity. J Clin Invest (1978) 0.85
Genetics of the complement system. J Med Genet (1975) 0.77
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry (1966) 15.12
THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO. J Exp Med (1965) 8.31
The properdin system and immunity. V. The bactericidal activity of the properdin system. J Exp Med (1956) 7.90
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
Quantitative studies on the bactericidal actions of serum and complement. I. A rapid photometric growth assay for bactericidal activity. J Immunol (1956) 5.66
Granulocyte chemotaxis: an improved in vitro assay employing 51 Cr-labeled granulocytes. J Immunol (1973) 4.61
A familial deficiency of the phagocytosis-enhancing activity of serum related to a dysfunction of the fifth component of complement (C5). N Engl J Med (1970) 4.42
Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Clin Invest (1971) 3.61
Homozygous deficiency of C3 in a patient with repeated infections. Lancet (1972) 3.04
Polymorphonuclear leukocyte chemotactic activity in rabbit serum and Guinea pig serum treated with immune complexes: evidence for c5a as the major chemotactic factor. Infect Immun (1970) 3.01
Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection. J Clin Invest (1970) 2.92
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med (1966) 2.73
The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria. J Clin Invest (1956) 2.68
A neutrophil chemotatic factor derived from C'5 upon interaction of guinea pig serum with endotoxin. J Immunol (1969) 2.54
C2 deficiency. Development of lupus erythematosus. J Clin Invest (1973) 2.52
Bactericidal and opsonic properties of C4-deficient guinea pig serum. J Immunol (1972) 2.48
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology (1970) 2.17
Hereditary C2 deficiency with some manifestations of systemic lupus erythematosus. J Immunol (1972) 2.02
Hereditary deficiency of the second component of complement (C'2) in man: further observations on a second kindred. J Immunol (1967) 1.98
A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med (1971) 1.97
IMMUNE BACTERICIDAL ACTIVITY OF COMPLEMENT. SEPARATION AND DESCRIPTION OF INTERMEDIATE STEPS. J Immunol (1964) 1.82
IDENTIFICATION OF THE COMPONENTS OF COMPLEMENT PARTICIPATING IN THE ANTIGLOBULIN REACTION. Immunology (1963) 1.76
Studies of an additional kindred with hereditary deficiency of the second component of human complement (C2) and description of a new method for the quantitation of C2. J Immunol (1968) 1.69
Inherited deficiency of the third component of human complement (C'3). J Clin Invest (1969) 1.56
Genetic aspects of the complement system. Adv Immunol (1971) 1.52
C1r deficiency: an inborn error associated with cutaneous and renal disease. J Clin Invest (1972) 1.52
The complement system of man (second of four parts). N Engl J Med (1972) 1.47
Deficiency of C1r in human serum. Effects on the structure and function of macromolecular C1. J Exp Med (1970) 1.36
The "sugar-water" test for paroxysmal nocturnal hemoglobinuria. N Engl J Med (1966) 1.36
Studies on chemotaxis. XII. Generation of chemotactic activity for polymorphonuclear leucocytes in sera with complement dificiencies. Immunology (1969) 1.31
Lupus-erythematosus-like syndrome with a familial defect of complement. N Engl J Med (1972) 1.30
Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells. J Clin Invest (1973) 1.29
Hereditary deficiency of the second component of complement in man: an immunochemical study. J Immunol (1969) 1.21
Hereditary deficiency of the sixth component of complement in man. II. Studies of hemostasis. J Clin Invest (1974) 1.20
Chemotaxis of polymorphonuclear leukocytes from patients with systemic lupus erythematosus and Felty's syndrome. Immunol Commun (1972) 1.18
Protective function of C6 in rabbits treated with bacterial endotoxin. J Immunol (1971) 1.10
Immune hemolysis. I. Differing susceptibility of three genetic types of sheep red cells. J Immunol (1972) 1.06
Purpura, arthralgia, and IgM-IgM cryoglobulinemia with rheumatoid factor acrivity. Response to cyclophosphamide and splenectomy. Ann Intern Med (1971) 1.06
Bacillus thuringiensis and its pesticidal crystal proteins. Microbiol Mol Biol Rev (1998) 13.47
Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol (1998) 5.69
The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors. J Exp Med (1969) 4.96
Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med (1979) 4.52
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Revision of the nomenclature for the Bacillus thuringiensis pesticidal crystal proteins. Microbiol Mol Biol Rev (1998) 4.14
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med (1996) 3.89
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. J Clin Invest (1972) 3.64
Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Clin Invest (1971) 3.61
Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum (1977) 3.51
The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol (1974) 3.38
Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med (1976) 3.10
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med (1971) 2.98
Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med (1976) 2.96
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest (1972) 2.82
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol (1974) 2.60
A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum (1986) 2.56
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: a feasibility study. Radiology (2001) 2.54
Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (1990) 2.49
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med (1983) 2.49
Bactericidal and opsonic properties of C4-deficient guinea pig serum. J Immunol (1972) 2.48
A receptor for the third component of complement in the human renal glomerulus. J Exp Med (1975) 2.39
Gene organization and regulation in the qa (quinic acid) gene cluster of Neurospora crassa. Microbiol Rev (1985) 2.33
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet (1981) 2.29
In vitro studies of complement function in sera of C4-deficient guinea pigs. J Exp Med (1971) 2.29
Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol (1986) 2.28
Nodular lymphoma--evidence for origin from follicular B lymphocytes. N Engl J Med (1974) 2.26
Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: studies in patients with dermatitis herpetiformis and normal subjects. N Engl J Med (1981) 2.19
Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology (1970) 2.17
Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathog (1987) 2.15
The effect of temperature on the reactivity of guinea-pig complement with gamma G and gamma M haemolytic antibodies. Immunology (1970) 2.14
Characterization of C1q receptor expression on human phagocytic cells: effects of PDBu and fMLP. J Immunol (1986) 2.09
Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore) (1977) 2.07
The localization of non-microbial antigens in the draining lymph nodes of tolerant, normal and primed rabbits. Immunology (1967) 2.07
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 2.05
Ontogeny of B lymphocytes. II. Relative rates of appearance of lymphocytes bearing surface immunoglobulin and complement receptors. J Exp Med (1974) 2.03
Micrococcus luteus -- survival in amber. Microb Ecol (2004) 2.02
Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA). J Immunol (1979) 2.01
Immunofluorescent demonstration of an IgG-B1C complex in synovial lining cells of rheumatoid synovial membrane. Clin Exp Immunol (1969) 2.00
In vivo studies in C4-deficient guinea pigs. J Exp Med (1971) 2.00
Hereditary deficiency of the second component of complement (C'2) in man: further observations on a second kindred. J Immunol (1967) 1.98
Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol (1984) 1.87
The critical role of complement in experimental pneumococcal sepsis. J Infect Dis (1980) 1.87
Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience. Ophthalmology (1997) 1.85
Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest (1971) 1.83
Complement depletion in cryptococcal sepsis. J Immunol (1978) 1.82
Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest (1972) 1.82
A simplified method for the measurement of chemotaxis of polymorphonuclear leukocytes from human blood. J Lab Clin Med (1971) 1.81
The complement system in host defense and inflammation. Rev Infect Dis (1980) 1.80
NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann Intern Med (1983) 1.79
NIH conference. Recent advances in chronic granulomatous disease. Ann Intern Med (1983) 1.76
Benefits and disadvantages of joint hypermobility among musicians. N Engl J Med (1993) 1.74
Basic tear flow. Does it exist? Ophthalmology (1980) 1.74
A new complement-mediated cytolytic mechanism--the C1-bypass activation pathway. Proc Natl Acad Sci U S A (1973) 1.74
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med (1984) 1.74
Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med (1972) 1.73
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol (1986) 1.72
C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med (1988) 1.67
Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med (1981) 1.65
The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis (1983) 1.63
Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption. Mol Microbiol (1993) 1.63
The subunits in rabbit anti-Forssman IgM antibody. J Exp Med (1968) 1.60
A simple method for the determination of complement receptor-bearing mononuclear cells. J Immunol (1976) 1.59
Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun (2001) 1.59
Hypermobility: features and differential incidence between the sexes. Arthritis Rheum (1987) 1.59
The effect of Bacillus Calmette-Guerin-induced macrophage activation on the in vivo clearance of sensitized erythrocytes. J Clin Invest (1974) 1.58
Haemophilus influenzae meningitis in an adult. A study of bactericidal antibodies and immunoglobulins. N Engl J Med (1970) 1.58
Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. J Clin Invest (1979) 1.58
Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore) (1979) 1.57
Lack of binding of human C3, in its native state, to C3b receptors. J Immunol (1981) 1.57
Inherited deficiency of the third component of human complement (C'3). J Clin Invest (1969) 1.56
Clinically atypical granular corneal dystrophy with pathologic features of lattice-like amyloid deposits. A study of these families. Ophthalmology (1988) 1.55
Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest (1974) 1.54
Immunologic responses to Hemophilus influenzae meningitis. J Pediatr (1972) 1.53
Extended-wear contact lenses and pseudomonal corneal ulcers. Am J Ophthalmol (1986) 1.53
Structure and dynamics of the acid-denatured molten globule state of alpha-lactalbumin: a two-dimensional NMR study. Biochemistry (1993) 1.52
Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages. J Immunol (1987) 1.51
Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis (1992) 1.49
Studies of isolated synovial living cells of rheumatoid and nonrheumatoid synovial membranes. Arthritis Rheum (1971) 1.49
Studies on the fibronectin receptors of human peripheral blood leukocytes. Morphologic and functional characterization. J Exp Med (1984) 1.48
Evidence that rabbit gamma G haemolysin in capable of utilizing guinea-pig complement more efficiently than rabbit gamma M haemolysin. Immunology (1970) 1.48
Demonstration of circulating immune complexes in Sjögren's syndrome. J Immunol (1979) 1.46
Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis (1978) 1.46
Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest (1978) 1.45
Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J Exp Med (1987) 1.44
Infection in rheumatoid arthritis. Arthritis Rheum (1971) 1.44